Absence of IL-23p19 in donor allogeneic cells reduces mortality from acute GVHD

Bone Marrow Transplantation

Volumn 45, Issue 4, 2010, Pages 712-722

  Thompson, J S ^a   Chu, Y ^a   Glass, J F ^a   Brown, S A ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

GVHD; IL 17; IL 22; IL 23p19

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23P19; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DISEASE SEVERITY; DONOR; GENE EXPRESSION REGULATION; GRAFT REJECTION; GRAFT SURVIVAL; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MORTALITY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; SPLEEN CELL; STRAIN DIFFERENCE; TH17 CELL; UPREGULATION; WHOLE BODY RADIATION;

ANIMALS; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; INTERLEUKIN-17; INTERLEUKIN-23 SUBUNIT P19; INTERLEUKINS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; RNA, MESSENGER; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; UP-REGULATION; WHOLE-BODY IRRADIATION;

EID: 77950616201     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.215     Document Type: Article

References (58)

1. Symington FW, Symington BE, Liu PY, Viquet H, Santhanam U, Sehgal PB. The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation. Transplantation 1992; 54: 457-462.
2. Ferrara JLM, Abhyankar S, Gilliland DG. Cytokine storm of graft-versus-host disease: a critical role of interleukin-1. Transpl Proc 1993; 25: 1216-1217.
3. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide or cyclophosphamide conditioning on inflammatory cytokines in H2 incompatible SCID mice. Blood 1994; 83: 2360-2367.
4. Xun CQ, Tsuchida M, Thompson JS. Delaying transplantation after total body irradiation is a simple and effective way to reduce aGVHD. Transplantation 1997; 64: 1-6.
5. Ferrara JL, Reddy P. Pathophysiology of graft-versus-hostdisease. Semin Hematol 2006; 43: 3-10.
6. Sykes M, Pearson DA, Taylor PA, Szot GL, Goldman SJ, Blazar BR. Dose and timing of interleukin (IL)-12 and timing and type of total body irradiation: effects on graft-versus-host disease inhibition and toxicity of exogenous IL-12 in murine bone marrow transplant recipients. Biol Blood Marrow Transplant 1999; 5: 277-284.
7. Yang YG. The role of interleukin-12 and interferon-gamma in GVHD and GVL. Cytokines Cell Mol Ther 2000; 6: 41-46.
8. Goriely S, Goldman M. The interleukin-12 family: new players in transplantation immunity. Am J Transplant 2006; 7: 278-284.
9. Alber G, Al-Robaly S, Kleinschek M, Knauer J, Krumbholz P, Richter J et al. Induction of immunity and inflammation by interleukin-12 family members. Ernst-Schering-Res Found Workshop 2006; 56: 107-127.
10. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240.
11. Kreymborg K, Bohlmann U, Becher B. IL-23 changing the verdict on IL-12 function in inflammation and autoimmunity. Expert Opin Ther Target 2005; 9: 1123-1136.
12. Hunter CA. New IL-12 family members: Il-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005; 5: P521-P531.
13. Chen Y, Langish CL, McKenzie B, Joyce-Sjaikjh B, Stumhofer JS, McClanahan T et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006; 116: 1317-1326.
14. Yen D, Cheung J, Scheerens H, Poulet P, McClanahan T, McKenzie B et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116: 1310-1316.
15. Li Y, Chu N, Hu A, Gran B, Rostami A, Zhang GX. Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain 2007; 130: 490-501.
16. Liu FL, Chen CH, Chu SJ, Chen JH, Lai JH, Sytwu HK et al. Interleukin (IL)-23p19 expression induced by IL-1beta in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-kappaB and AP-1 dependent pathway. Rheumatology 2007; 46: 1266-1273.
17. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007; 8: 461-467.
18. Zhang Z, Andoh A, Yasui H, Inatomi O, Hata K, Tsuijikawa T et al. Interleukin -1beta and tumor necrosis factor-alpha upregulate interleukin-23 subunit p19 gene expression in human colonic subepithelial myofibroblasts. Int J Mol Med 2005; 15: 79-83.
19. Cho ML, Kang JW, Moon YM, Nam HJ, Jhun JY, Heo SB et al. STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol 2006; 176: 5652-5661.
20. Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, Tahara H. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with endogenously expressed IL-12. J Immunol 2007; 178: 7671-7680.
21. Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Target 2009; 8: 40-52.
22. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004; 21: 467-476.
23. Yamaguchi Y, Fujio K, Shoda H, Okamoto A, Tsuno NH, Takahashi K et al. IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis. J Immunol 2007; 179: 7128-7136.
24. Witowski J, Ksiazek K, Jorres A. Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci 2004; 61: 567-579.
25. Miyamota M, Prause O, Sjostrand M, Laan M, Lotvali J, Linden A. Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways. J Immunol 2003; 170: 4665-4672.
26. Lohr J, Knoechal B, Wang JJ, Villarino AV, Abbas AK. The role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med 2006; 203: 2785-2791.
27. Irmler IM, Gajda M, Brauer R. Exacerbation of antigeninduced arthritis in IFN-gamma deficient mice as a result of unrestricted IL-17 response. J Immunol 2007; 179: 6228-6236.
28. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006; 116: 1218-1222.
29. Antonysamy MA, Fanslow WC, Fu F, Qian S, Trout AB, Thomson AW. A novel IL-17 antagonist promotes heart graft survival. Transplant Proc 1999; 31: 93.
30. Tang H, Subbotin VM, Antonysamy MA, Truot AG, Rao AS, Thomson AW. Interleukin-17 antagonism inhibits acute but not chronic vascular rejection. Transplantation 2001; 72: 348-350.
31. Chen Y, Wood KJ. Interleukin-23 and Th17 cells in transplantation immunity: does IL-23+IL-17 equal rejection? Transplantation 2007; 84: 1071-1074.
32. Afsali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007; 148: 32-46.
33. Yaun X, Paez-Cortez J, Schmitt-Knosalla I, D'Addio F, Mfarrej B, Dnnarumma M et al. A novel role of CD4Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008; 205: 3133-3144.
34. Fabrega E, Lopez-Hoyos M, San Segundo D, Casafont F, Pons-Romero F. Changes in the serum levels of interleukin-17/ interleukin-23 during acute rejection in liver transplantation. Liver Transplant 2009; 15: 629-633.
35. Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR. Absence of regulatory T control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 2007; 110: 3804-3813.
36. Mauermann N, Burian J, von Garnier C, Dirnhofer S, Germano D, Schuett C et al. Interferon-g regulates idiopathic pneumonia syndrome, a Th17+CD4+ T-cell-mediated graft-versus-host disease. Resp Crit Care Med 2008; 178: 379-388.
37. Kappel LW, Gabarielle GL, King CG, Suh DY, Smith OM, Ligh C et al. Vvan den Brink MRM. IL-17 contributes to CD4-mediaed graft-versus-host disease. Blood 2009; 113: 945-952.
38. Carlson MJ, West ML, Coghill JM, Panoskaitsis-Mortan A, Blazer BR, Serody JS. In vitro differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathological manifestations. Blood 2009; 113: 1365-1374.
39. Das R, Chen X, Komorowski R, Hessner MJ, Drobyski WR. Interleukin-23 secretion in donor antigen-presenting cells is critical for organ-specific pathology in graft-versus-host disease. Blood 2009; 113: 2352-2362.
40. Thompson J, Chu Y, Glass J, Brown S. IL-23 plays a critical role in the pathogenesis of acute but not chronic graft versus host disease. Transplantation 2008; 86(Suppl 2): 357.
41. Liu SJ, Tsai JP, Shen CR, Sher YP, Hsieh CL, Yeh YC et al. Induction of CD8 Tnc17 subset by transforming growth factor-beta and interleukin-6. J Leukoc Biol 2007; 82: 354-360.
42. Burrell BE, Csencits KI, Lu G, Grabauskiene S, Bishop DK. CD8+Th17 mediate co-stimulation blockade-resistant allograft rejection in T-beta-deficient mice. J Immunol 2008; 181: 3906-3914.
43. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T et al. Littman IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007; 8: 967-974. (Pubitemid 47300011)
44. Bettelli E, Carrier Y, Gao W, Korn T, Stroim TB, Oukkka MJ et al. Reciprocal developmental pathways for the generation of pathogenetic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238.
45. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ et al. The orphan nuclear receptor RORgamma t directs the differentiation program of proinflammatory IL- 17+ T helper cells. Cell 2006; 126: 1121-1133. (Pubitemid 44380299)
46. Huang Z, Xie H, Wang R, Sun Z. Retinoid-related orphan receptor gamma t is a potential therapeutic target for controlling inflammatory autoimmunity. Exper Opin Ther Targets 2007; 11: 737-743. (Pubitemid 46901394)
47. Mowat AM. Antibodies to IFNg prevent immunologically mediated intestinal damage in murine graft-versus-host reaction. Immunology 1989; 68: 18-23.
48. Niederwieser D, Herold M, Woloszczuk W, Aulitzky W, Meister B, Tilg H et al. Endogenous INF-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation 1990; 50: 620-625. (Pubitemid 20358535)
49. Yang YG, Dey BR, Sergio JJ, Perason DA, Sykes M. Donorderived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin-12. J Clin Invest 1998; 102: 2126-2135. (Pubitemid 29018819)
50. Krenger W, Falzarno G, Selmonte J, Synder KM, Byon JCH, Ferrara JLM. Interferon-g suppresses T-cell proliferation to mitogen via nitric oxide pathway during experimental graftversus- host disease. Blood 1996; 88: 1113-1121. (Pubitemid 26333339)
51. Wolk K, Sabat R. Interleukin-22: a novel T and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 2006; 17: 367-380. (Pubitemid 44572879)
52. Liang SC, Tan XY, Luxengerg DP, Karim R, Dunussi- Joannopoulos K, CollinsMet al. Interleukin (IL) 22 and IL-17 are coexpressed on Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203: 2271-2279. (Pubitemid 44498362)
53. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q et al. Interleukin -22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008; 14: 282-289. (Pubitemid 351347912)
54. Wolk K, Witte E, Wallace E, Docke WD, Kunz S, Asadiah K et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006; 36: 1309-1323.
55. Brand S, Beigel F, Zitzmann K, Eichhorst ST, Otte JM, Diepolder H et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006; 290: G827-G838.
56. Kapessidou P, Poulin L, Dumoutier L, Goldman M, Renauld JC, Braun MY. Interleukin-22 deficiency accelerates the rejection of full major histocompatibility complex-disparate heart allografts. Transplant Proc 2008; 40: 1593-1597. (Pubitemid 351863746)
57. Uyttenhove C, Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol 2005; 36: 2868-2874. (Pubitemid 44782560)
58. Bowman EP, Chacfkerian AA, Cua DJ. Rationale and safety of anti-interleukin-23 and anti-interleukin 17A therapy. Curr Opin Infect Dis 2006; 19: 245-252.